Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
This study has been terminated.
( Trial was withdrawn for drug availability issues. )
Study NCT00066417 Information provided by National Cancer Institute (NCI)
First Received: August 6, 2003 Last Updated: January 24, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Additional conditions recognized in this trial
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
cyclophosphamide
cyclosporine
fludarabine phosphate
methylprednisolone
therapeutic allogeneic lymphocytes
thiotepa
biological therapy
bone marrow transplantation
chemotherapy
leukocyte therapy
peripheral blood lymphocyte therapy
radiation therapy
Additional drug interventions recognized in this trial
Cyclosporins
Fludarabine
Fludarabine monophosphate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Vidarabine
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Anti-Inflammatory Agents
Antiemetics
Antifungal Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antirheumatic Agents
Antiviral Agents
Autonomic Agents
Central Nervous System Agents
Dermatologic Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
National Heart, Lung, and Blood Institute (NHLBI)
Back to top of Main Content
